RxDoctor Payments Data

Irfan Chughtai, MD

Nephrology · Meriden, CTNPI 1477538973

Payments from drug & device makers

$462in general payments, 2019–2025

Across 13 payments — averaging $35.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Baxter Healthcare$125
  • AstraZeneca$99
  • Akebia Therapeutics Inc$53
  • Otsuka America Pharmaceutical, Inc.$49
  • Travere Therapeutics, Inc.$46
  • Kyowa Kirin, Inc.$27
  • plus $64 from 3 others

What the payments were for

  • Food & beverage$34174%
  • Education$12126%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$462 in reported general payments places this provider in the 40th percentile of 144 nephrology providers in Connecticut.

See all nephrology providers in Connecticut

Medicare billing

Part B allowed, 2024
$334,137
Medicare patients
479
Services billed
2,115

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide19$58,962
Sevelamer Carbonate102$12,310
ProsolParenteral Amino Acid 20% No.1102$12,200
LokelmaSodium Zirconium Cyclosilicate11$9,802
Potassium Citrate ErPotassium Citrate100$6,395
Bumetanide44$2,376
Calcium Acetate25$1,741
Torsemide64$1,560
Potassium Chloride98$1,555
Doxazosin Mesylate100$1,508
Calcitriol115$1,500
Furosemide261$1,400
Amlodipine Besylate232$1,231
Chlorthalidone79$1,213
Losartan Potassium123$1,197

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaLokelma$99$9,80211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 144 nephrology providers in Connecticut.

Other nephrology in Meriden

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →